BIO.B · NYSE
Bio-Rad Laboratories (BIO.B) Stock Price & Fundamentals
Bio-Rad Laboratories (BIO.B) closed at $476.75 on Oct 9, 2026, down 0.38% from the previous close of $478.55.
Share price, past year
1Y −0.34%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $476.75 |
| Sep 30, 2026 | $463.49 |
| Aug 31, 2026 | $478.79 |
| Jul 31, 2026 | $495.74 |
| Jun 30, 2026 | $486.89 |
| May 29, 2026 | $513.70 |
| Apr 30, 2026 | $496.38 |
| Mar 31, 2026 | $464.14 |
| Feb 27, 2026 | $503.96 |
| Jan 30, 2026 | $488.23 |
| Dec 31, 2025 | $486.98 |
| Nov 28, 2025 | $468.90 |
| Oct 31, 2025 | $463.62 |
Key statistics
- Market cap
- —
- P/E (TTM)
- 58.2
- EPS (TTM)
- $8.19
- Revenue (TTM)
- $2.59B
- Net income (TTM)
- $222.40M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $455.89 – $517.40
Financials
Bio-Rad Laboratories reported revenue of $2.58B for fiscal 2025, up 0.65% from fiscal 2024.
Bio-Rad Laboratories earned net income of $759.90M in fiscal 2025, a net margin of 29.4%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.58B | +0.7% | $759.90M | 29.4% | $27.85 | $374.60M |
| FY2024ended Dec 31, 2024 | $2.57B | −3.9% | −$1.84B | −71.9% | −$65.36 | $289.60M |
| FY2023ended Dec 31, 2023 | $2.67B | −4.7% | −$637.30M | −23.9% | −$21.82 | $218.20M |
| FY2022ended Dec 31, 2022 | $2.80B | −4.1% | −$3.63B | −129.5% | −$121.79 | $81.60M |
| FY2021ended Dec 31, 2021 | $2.92B | +14.8% | $4.25B | 145.6% | $140.83 | $535.72M |
| FY2020ended Dec 31, 2020 | $2.55B | +10.1% | $3.81B | 149.8% | $126.47 | $476.41M |
| FY2019ended Dec 31, 2019 | $2.31B | +1.0% | $1.76B | 76.1% | $58.27 | $359.37M |
| FY2018ended Dec 31, 2018 | $2.29B | +6.0% | $365.61M | 16.0% | $12.10 | $155.67M |
| FY2017ended Dec 31, 2017 | $2.16B | +4.5% | $122.25M | 5.7% | $4.07 | −$7.20M |
| FY2016ended Dec 31, 2016 | $2.07B | — | $26.00M | 1.3% | $0.88 | $74.63M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $651.00M | $371.40M | $13.85 |
| Q1 FY2026ended Mar 31, 2026 | $592.10M | −$527.10M | −$19.55 |
| Q4 FY2025ended Dec 31, 2025 | $693.20M | $720.00M | $26.59 |
| Q3 FY2025ended Sep 30, 2025 | $653.00M | −$341.90M | −$12.70 |
| Q2 FY2025ended Jun 30, 2025 | $651.60M | $317.80M | $11.67 |
| Q1 FY2025ended Mar 31, 2025 | $585.40M | $64.00M | $2.29 |
| Q4 FY2024ended Dec 31, 2024 | $667.50M | −$715.80M | −$25.57 |
| Q3 FY2024ended Sep 30, 2024 | $649.70M | $653.20M | $23.34 |
Company profile
- Name
- Bio-Rad Laboratories, Inc.
- Ticker
- BIO.B
- Exchange
- NYSE
- Industry (SEC SIC)
- Laboratory Analytical Instruments
- Headquarters
- 1000 Alfred Nobel Drive, Hercules, CA 94547
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000012208
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Apr 30, 2026
- Apr 30, 2026
- Apr 24, 2026
- Feb 19, 2026
- Feb 13, 2026
- Feb 12, 2026
Frequently asked questions
What is Bio-Rad Laboratories's stock price?
Bio-Rad Laboratories (BIO.B) closed at $476.75 on Oct 9, 2026, down 0.38% from the previous close of $478.55.
How much revenue does Bio-Rad Laboratories make?
Bio-Rad Laboratories reported revenue of $2.58B for fiscal 2025, up 0.65% from fiscal 2024.
What is BIO.B's P/E ratio?
Bio-Rad Laboratories's price-to-earnings ratio is 58.2, based on trailing twelve-month diluted EPS of $8.19.
Does Bio-Rad Laboratories pay a dividend?
Bio-Rad Laboratories's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Bio-Rad Laboratories, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures